Evidence map›Paper›PMID 35262294›Full record

ArticleProblemy endokrinologii2021

[Features of the use of synthetic analogues of thyroid hormones: а 2020 THESIS* questionnaire survey of members of the Belarusian Public Medical Association of Endocrinology and Metabolism].

A P Shepelkevich, Yu V Dydyshka, E V Yurenya, V L Lоbashova, R Attanasio, L Hegedüs, E Nagy, R Negro, E Papini, P Perros

Open access · diamondAbstract read
In one paragraph

Article in Problemy endokrinologii, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Enhanced Well-Being Associated with Thyrotoxicosis: A Neglected Effect of Thyroid Hormones?International journal of endocrinology and metabolism · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 9 institutions in 7 countries.

A P ShepelkevichBelarusian State Medical University.
Yu V DydyshkaBelarusian State Medical University; Republic Center of Endocrinology and Medical Rehabilitation.
E V YurenyaMinsk City Clinical Endocrinological Center.
V L LоbashovaRepublic Center of Endocrinology and Medical Rehabilitation.
R AttanasioIRCCS Orthopedic Institute Galeazzi.
L HegedüsOdense University Hospital.
E NagyUniversity of Debrecen.
R Negro"V. Fazzi" Hospital.
E PapiniOspedale Regina Apostolorum.
P PerrosRoyal Victoria Infirmary.
Belarusian State Medical University · BY9th City Clinical Hospital · BYIstituti di Ricovero e Cura a Carattere Scientifico · ITNational Rehabilitation Center · KROdense University Hospital · DKOspedale Regina Apostolorum · ITOspedale Vito Fazzi · ITRoyal Victoria Infirmary · GBUniversity of Debrecen · HU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe standard treatment for hypothyroidism is levothyroxine (LT4), which in the Republic of Belarus is available in tablet form whereas liothyronine (LT3) is not registered, but patients can purchase them on their own abroad.

aimThis study aimed to investigate Belarusian endocrinologists' attitude of thyroid hormones in hypothyroid and euthyroid patients. MATERIALS AND

methodsAn online survey was conducted, for which members of the Belarusian Medical Association of Endocrinology and Metabolism were invited by posting information in the group chat and by e-mail. The research period was from October 1 to December 26, 2020. 210 questionnaires were received, 146 of which were used.

resultsThe majority of participants, 145 (99.3%), indicated that they were using LT4 as the first-choice drug for the treatment hypothyroidism. Sixty-one (41.8%) doctors answered that LT3 + LT4 combination likely can be used in patients with long-term untreated hypothyroidism and 15 (10.3%) - in patients with persistent symptoms of hypothyroidism, despite biochemical euthyroidism on therapy LT4. Over half of the respondents 84 (57.5%) answered that thyroid hormone therapy was never indicated for euthyroid patients, but 50 (34.2%) would consider it for female infertility with high level of thyroid antibodies and 36 (24.7%) for simple goiter growing over time. In various conditions that could interfere with absorption of LT4, most responding Belarusian endocrinologists do not expect a significant difference with different formulations (tablets+"I do not expect major changes in different forms" vs. "soft gel capsules"+"liquid solution"; p <0.001). Persistent symptoms of hypothyroidism on the background of LT4 replacement therapy with the achievement of the target TSH can mainly be caused by psychosocial factors, concomitant diseases, unrealistic patient expectations, chronic fatigue syndrome, and the burden of chronic disease.

conclusionThe method of choice of Belarusian endocrinologists in the treatment of hypothyroidism is LT4 replacement therapy, but the appointment of LT4 + LT3 combination therapy can be considered in certain clinical situations. As a rule, endocrinologists do not prescribe LT4 in patients with euthyroidism and do not expect a significant difference when using other forms of levothyroxine.

Indexed as

HypothyroidismThyroxineFemaleHumansSurveys and QuestionnairesThyroid HormonesTriiodothyronineThyroid HormonesThyroxineTriiodothyronine

Identifiers

PMID35262294
PMCPMC9112860
OpenAlexW4225998034

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.